The December issue of highlights new clinical science and reviews, including outcomes among transgender adults with cirrhosis, risk factors for inadequate bowel preparation, and upadacitinib versus tofacitinib in ulcerative colitis. This month we also published articles on celiac disease, belching disorders, eosinophilic esophagitis, pancreatitis, and more.
Several articles are highlighted below and access to any articles from this issue, or past issues, is available upon request. The College is also able to connect members of the press with study authors or outside experts who can comment on the articles.
Beran, et al.
This meta-analysis included 154 studies with 358,257 participants to identify risk factors for inadequate bowel preparation (IBP). The authors analyzed 48 unique risk factors and found that sociodemographic predictors of IBP were Medicaid insurance, obesity, current tobacco use, age ≥ 65 years, Black race, low education level, male sex, and unmarried status. They noted that, “Our findings could help develop a validated prediction model to identify high-risk patients for IBP, improve colonoscopy outcomes, reduce the need for repeat colonoscopies, and reduce the associated healthcare costs.”
Elhence, et al.
In this study, the authors compared transgender and cis-gender adults with cirrhosis who are commercially insured. They found that cirrhosis is twice as prevalent among transgender adults, and the majority have a diagnosis of anxiety and/or depression.
Kochhar, et al.
In a retrospective cohort study using a multi-institutional database, the authors compared the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis (UC) to assess the risk of a composite outcome of hospitalization requiring intravenous steroids and/or colectomy within six and 12 months. Their findings indicate that upadacitinib was associated with improved disease-specific outcomes at 12 months compared with tofacitinib in patients with UC.
About the American College of Gastroenterology
Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 19,000 individuals from 86 countries. The College's vision is to be the preeminent organization supporting health care professionals who provide compassionate, equitable, high-quality, state-of-the-art, and personalized care to promote digestive health. The mission of the College is to provide tools, services, and accelerate advances in patient care, education, research, advocacy, practice management, professional development and clinician wellness, enabling our members to improve patients’ digestive health and to build personally fulfilling careers that foster well-being, meaning and purpose. Follow ACG on X @AmCollegeGastro and learn more at .
RSS